{
  "first_published_at": "2014-08-04", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON444288", 
  "title": "Ofatumumab▼: reminder of risk of serious and fatal infusion reactions—always give premedication and monitor patients carefully", 
  "tags": "{\"parsed_therapeutic\": [\"cancer\"], \"Audience:\": [\"Secondary care\"], \"Therapeutic area:\": [\"Cancer\"]}", 
  "_document_number": 17, 
  "label": "Reminder", 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "cancer"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Ofatumumab&#9660;: reminder of risk of serious and fatal infusion reactions&#8212;always give premedication and monitor patients carefully</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: August 2014</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br><p>Serious and fatal infusion reactions have occurred with ofatumumab and other anti-CD20 monoclonal antibodies. We remind you to always give premedication before each ofatumumab infusion. If a severe reaction occurs, interrupt ofatumumab infusion and treat the reaction. Patients with a history of decreased pulmonary function are at high risk of pulmonary complications from severe reactions</p><br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Ofatumumab&#9660; (Arzerra&#9660;) is indicated for the treatment of patients with chronic lymphocytic leukaemia (CLL) refractory to fludarabine and alemtuzumab.</p>\n\n<p>Infusion reactions have occurred with intravenous ofatumumab. A fatal infusion reaction has occurred during administration of the first dose of ofatumumab to a 71 year old man.</p>\n\n<p>We remind you of the recommendations to reduce the risk of infusion reactions with ofatumumab:</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<ul>\n<li>Ofatumumab should only be given under the supervision of a physician experienced in the use of cancer therapy and where facilities to monitor and treat infusion reactions are available</li>\n\n<li>Always give patients premedication 30 minutes to 2 hours before each ofatumumab infusion according to the protocol in the summary of product characteristics (see further information below)</li>\n\n<li>Despite premedication, infusion reactions may still occur</li>\n\n<li>If an infusion reaction occurs, interrupt ofatumumab infusion immediately and treat the symptoms of the reaction</li>\n\n<li>Patients with a history of decreased pulmonary function may be at a high risk of pulmonary complications from severe reactions. Monitor these patients closely during ofatumumab infusion.</li>\n</ul>\n</div>\n\n<p><strong>Related medicines</strong></p>\n\n<p>Infusion reactions have also occurred with other anti-CD20 monoclonal antibodies such as rituximab (MabThera) and obinutuzumab (Gazyvaro). Specific recommendations to reduce the risk of infusion reactions for each of these products, including the use of pre-medications, are in the summary of product characteristics for each product (see further information below).</p>\n\n<p><strong>Further information</strong></p>\n\n<p><a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/Medicinesinformation/SPCandPILs/index.htm\">Summaries of product characteristics&#160;</a></p>\n\n<p><a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON439844\">Letter sent to healthcare professionals in July 2014&#160;</a></p>\n\n<p><em>Article citation: Drug Safety Update volume 8 issue 1, August 2014: A2.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Ofatumumab&#9660; (Arzerra&#9660;) is indicated for the treatment of patients with chronic lymphocytic leukaemia (CLL) refractory to fludarabine and alemtuzumab.</p>\n\n<p>Infusion reactions have occurred with intravenous ofatumumab. A fatal infusion reaction has occurred during administration of the first dose of ofatumumab to a 71 year old man.</p>\n\n<p>We remind you of the recommendations to reduce the risk of infusion reactions with ofatumumab:</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<ul>\n<li>Ofatumumab should only be given under the supervision of a physician experienced in the use of cancer therapy and where facilities to monitor and treat infusion reactions are available</li>\n\n<li>Always give patients premedication 30 minutes to 2 hours before each ofatumumab infusion according to the protocol in the summary of product characteristics (see further information below)</li>\n\n<li>Despite premedication, infusion reactions may still occur</li>\n\n<li>If an infusion reaction occurs, interrupt ofatumumab infusion immediately and treat the symptoms of the reaction</li>\n\n<li>Patients with a history of decreased pulmonary function may be at a high risk of pulmonary complications from severe reactions. Monitor these patients closely during ofatumumab infusion.</li>\n</ul>\n</div>\n\n<p><strong>Related medicines</strong></p>\n\n<p>Infusion reactions have also occurred with other anti-CD20 monoclonal antibodies such as rituximab (MabThera) and obinutuzumab (Gazyvaro). Specific recommendations to reduce the risk of infusion reactions for each of these products, including the use of pre-medications, are in the summary of product characteristics for each product (see further information below).</p>\n\n<p><strong>Further information</strong></p>\n\n<p><a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/Medicinesinformation/SPCandPILs/index.htm\">Summaries of product characteristics</a></p>\n\n<p><a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON439844\">Letter sent to healthcare professionals in July 2014</a></p>\n\n<p><em>Article citation: Drug Safety Update volume 8 issue 1, August 2014: A2.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2014-08-01", 
  "date_last_modified": "2014-08-07", 
  "_assets": [], 
  "_item_id": 17, 
  "summary": "Serious and fatal infusion reactions have occurred with ofatumumab and other anti-CD20 monoclonal antibodies. We remind you to always give premedication before each ofatumumab infusion. If a severe reaction occurs, interrupt ofatumumab infusion and treat the reaction. Patients with a history of decreased pulmonary function are at high risk of pulmonary complications from severe reactions", 
  "body": "Article date: August 2014\n\nOfatumumab▼ (Arzerra▼) is indicated for the treatment of patients with chronic lymphocytic leukaemia (CLL) refractory to fludarabine and alemtuzumab.\n\nInfusion reactions have occurred with intravenous ofatumumab. A fatal infusion reaction has occurred during administration of the first dose of ofatumumab to a 71 year old man.\n\nWe remind you of the recommendations to reduce the risk of infusion reactions with ofatumumab:\n\nAdvice for healthcare professionals:  \n  \n  * Ofatumumab should only be given under the supervision of a physician experienced in the use of cancer therapy and where facilities to monitor and treat infusion reactions are available  \n  * Always give patients premedication 30 minutes to 2 hours before each ofatumumab infusion according to the protocol in the summary of product characteristics (see further information below)  \n  * Despite premedication, infusion reactions may still occur  \n  * If an infusion reaction occurs, interrupt ofatumumab infusion immediately and treat the symptoms of the reaction  \n  * Patients with a history of decreased pulmonary function may be at a high risk of pulmonary complications from severe reactions. Monitor these patients closely during ofatumumab infusion.  \n  \nRelated medicines\n\nInfusion reactions have also occurred with other anti-CD20 monoclonal antibodies such as rituximab (MabThera) and obinutuzumab (Gazyvaro). Specific recommendations to reduce the risk of infusion reactions for each of these products, including the use of pre-medications, are in the summary of product characteristics for each product (see further information below).\n\nFurther information\n\n[Summaries of product characteristics](http://www.mhra.gov.uk/Safetyinformation/Medicinesinformation/SPCandPILs/index.htm)\n\n[Letter sent to healthcare professionals in July 2014](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON439844)\n\nArticle citation: Drug Safety Update volume 8 issue 1, August 2014: A2.\n"
}